loading...| Preferred Name |
Daclizumab |
|
| Synonyms |
|
|
| Definitions |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1569 |
|
| Accepted_Therapeutic_Use_For |
Kidney transplant rejection, prevention |
|
| ALT_DEFINITION |
A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count). |
|
| CAS_Registry |
152923-56-3 |
|
| code |
C1569 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. |
|
| Display_Name |
Daclizumab |
|
| FDA_UNII_Code |
CUJ2MVI71Y |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Daclizumab |
|
| Legacy Concept Name |
Daclizumab |
|
| Maps_To |
Daclizumab |
|
| NCI_Drug_Dictionary_ID |
42006 |
|
| NSC Number |
725173 |
|
| PDQ_Closed_Trial_Search_ID |
42006 |
|
| PDQ_Open_Trial_Search_ID |
42006 |
|
| Preferred_Name |
Daclizumab |
|
| prefixIRI |
NCIT:C1569 |
|
| prefLabel |
Daclizumab |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C0663182 |
|
| subClassOf |